How Multi-Target Peptide Drugs Like Tirzepatide Became Weight Loss Blockbusters | Research

The takeaway

A review of how single molecules designed to hit multiple hormone receptors simultaneously — like tirzepatide and retatrutide — have achieved record-breaking weight loss results for obesity and diabetes.

2.5 billion adults affected
Obesity and type 2 diabetes impact over 2.5 billion adults worldwide, driving demand for more effective multi-target treatments

What the researchers found

This review examines how unimolecular polypharmacology — designing single molecules that hit multiple receptors simultaneously — has transformed obesity and diabetes treatment. Blockbuster drugs like tirzepatide (GLP-1/GIP dual agonist) and retatrutide (GLP-1/GIP/glucagon triple agonist) have achieved unprecedented weight loss and blood sugar control, surpassing what single-receptor agonists can do.

Tirzepatide in particular has demonstrated remarkable effectiveness for weight loss, glycemic control, and additional cardiovascular and kidney benefits. However, the review also addresses ongoing challenges: gastrointestinal side effects, patient compliance (particularly with injections), and the problem of weight rebound when treatment stops.

Why it matters

With over 2.5 billion adults affected by obesity and type 2 diabetes globally, the development of multi-receptor agonists represents one of the most important pharmaceutical advances in decades. This review from Annual Review of Pharmacology and Toxicology provides a comprehensive framework for understanding why targeting multiple receptors with a single molecule works better than hitting just one — and what challenges remain before these drugs reach their full potential.

The numbers in context

2.5 billion adults affected by obesity/T2DM · Tirzepatide: dual GLP-1/GIP agonist · Retatrutide: triple GLP-1/GIP/glucagon agonist · Superior efficacy vs single agonists

How the study worked

This is a comprehensive review article published in Annual Review of Pharmacology and Toxicology, covering the development, mechanisms, clinical efficacy, and challenges of unimolecular multi-receptor agonists for metabolic diseases.

Who was studied

Review covering clinical trial data in obesity and T2DM populations

What this study cannot tell us

As a review, it synthesizes existing literature rather than presenting new data. The field is moving extremely fast, and clinical trial results continue to emerge. Long-term safety data for these newer multi-agonists is still limited. The review acknowledges but may understate the significance of weight rebound and GI side effect challenges.

How to read the evidence

This is a review in Annual Review of Pharmacology and Toxicology — a top-tier review journal. It synthesizes strong clinical trial evidence from blockbuster drugs including tirzepatide (FDA-approved) and retatrutide (phase 3). The underlying evidence base is robust.

When this study was published

Published in 2025. Extremely current review capturing the latest developments in multi-agonist metabolic drugs. Highly relevant to the current therapeutic landscape.

The bigger picture

The shift from single-target to multi-target peptide drugs represents a paradigm change in metabolic medicine. Semaglutide (single GLP-1 agonist) was groundbreaking, but tirzepatide's dual agonism roughly doubled the weight loss. Retatrutide's triple agonism pushes it further. The obvious question is: how many receptors can you target at once? Quad-agonists and combination approaches (like CagriSema adding amylin) are already in development. This review captures the field at a pivotal moment.

Questions still open

Is there a ceiling to how many receptors a single molecule can productively target?
Can the weight rebound problem be solved through maintenance dosing, combination approaches, or lifestyle interventions?
Will oral formulations of multi-agonists solve the compliance issues associated with injectable delivery?

Common questions

What is unimolecular polypharmacology?

It means designing a single molecule that can activate multiple hormone receptors at the same time. Instead of combining two separate drugs, scientists engineer one peptide that does the work of two or three. Tirzepatide, for example, is a single molecule that activates both GLP-1 and GIP receptors, achieving more weight loss than drugs that target just one receptor.

Why do multi-target drugs work better for weight loss than single-target ones?

Your body controls weight through multiple hormone systems, not just one. Hitting only the GLP-1 pathway helps, but adding GIP activation (tirzepatide) or GIP plus glucagon activation (retatrutide) engages additional mechanisms for reducing appetite, burning fat, and controlling blood sugar. Each additional target adds to the overall effect, which is why tirzepatide produces more weight loss than semaglutide, and retatrutide may exceed tirzepatide.

Read the original research

Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.

Annual review of pharmacology and toxicology, 65(1), 191-213

View on PubMed ↗Publisher’s paper ↗

Citation

Zhou, Qingtong; Li, Guanyi; Hang, Kaini; Li, Jie; Yang, Dehua; Wang, Ming-Wei. (2025). Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.. Annual review of pharmacology and toxicology, 65(1), 191-213. https://doi.org/10.1146/annurev-pharmtox-061324-011832